argenx SE
NASDAQ:ARGX

Watchlist Manager
argenx SE Logo
argenx SE
NASDAQ:ARGX
Watchlist
Price: 591.99 USD 2.88% Market Closed
Market Cap: 35.4B USD

Net Margin
argenx SE

41.2%
Current
25%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
41.2%
=
Net Income
1.1B
/
Revenue
2.6B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
NL
argenx SE
XBRU:ARGX
30.6B EUR
41%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
336.1B USD
7%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 848%
US
Amgen Inc
NASDAQ:AMGN
164.8B USD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
144.7B USD
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
129.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.9B USD
32%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

argenx SE
Glance View

In a landscape where biotechnology companies tirelessly strive to transform scientific insight into therapeutic breakthroughs, argenx SE stands out with its innovative approach to harnessing the body's own immune system to address severe autoimmune diseases. Originating from the biopharmaceutical hubs of Belgium and the Netherlands, argenx was founded in 2008 and has since positioned itself at the forefront of immunology. At the heart of argenx's operations lies its proprietary SIMPLE Antibody™ technology platform, which engineers differentiated therapeutic antibodies. Guided by a deep understanding of disease biology, the company partners closely with academic institutions and leading pharmaceutical companies to transform promising research insights into viable drug candidates. The company's financial sustenance is woven into its intricate business model, which revolves around the development and commercialization of therapeutic antibodies. Their flagship product, efgartigimod, has made significant strides in treating autoimmune diseases such as generalized myasthenia gravis, showcasing the company's ability to translate its scientific endeavors into substantial revenue streams. Argenx generates income primarily through product sales, milestone payments, and royalties from collaborative partnerships. As the company continues to advance its pipeline and expand its global presence, it demonstrates a robust commitment to addressing unmet medical needs while maintaining a keen eye on sustainable growth and profitability. This delicate balance of innovation and financial acumen allows argenx to reinforce its position in the competitive biotech industry.

ARGX Intrinsic Value
566.44 USD
Overvaluation 4%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
41.2%
=
Net Income
1.1B
/
Revenue
2.6B
What is the Net Margin of argenx SE?

Based on argenx SE's most recent financial statements, the company has Net Margin of 41.2%.

Back to Top